18th Feb 2019 17:13
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr N Hirons | |||
b) | Position/status | SVP, Global Ethics and Compliance | |||
c) | Initial notification/ amendment | Initial Notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Nature of the transaction | The exercise of nil-cost options over Ordinary Shares granted on 11 February 2016 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £0.0000 | 15,914 (Deferred) |
| ||
| £0.0000 | 9,392 (Matching) |
| ||
|
|
|
| ||
d) | Aggregated information |
| |||
Aggregated volume Price | 25,306 £0.0000 | ||||
e) | Date of the transaction | 2019-02-15 | |||
f) | Place of the transaction
| n/a | |||
1. | Details of PDMR/person closely associated with them ('PCA') |
| ||||
a) | Name | Mr N Hirons |
| |||
b) | Position/status | SVP, Global Ethics and Compliance |
| |||
c) | Initial notification/ amendment | Initial Notification |
| |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| ||||
a) | Name | GlaxoSmithKline plc |
| |||
b) | LEI | 5493000HZTVUYLO1D793 |
| |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
| |||
b) | Nature of the transaction | The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 15 February 2019 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. |
| |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
| |
| £15.9006 | 7,500 (Deferred) |
| |||
| £15.9006 | 4,425 (Matching) |
| |||
|
|
|
| |||
d) | Aggregated information |
|
| |||
Aggregated volume Price | 11,925 £15.9006 |
| ||||
e) | Date of the transaction | 2019-02-15 |
| |||
f) | Place of the transaction
| London Stock Exchange (XLON) |
| |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr D Redfern | |||
b) | Position/status | Chief Strategy Officer | |||
c) | Initial notification/ amendment | Initial Notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Nature of the transaction | The exercise of nil-cost options over Ordinary Shares granted on 11 February 2016 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £0.0000 | 20,254 (Deferred) |
| ||
| £0.0000 | 11,952 (Matching) |
| ||
|
|
|
| ||
d) | Aggregated information |
| |||
Aggregated volume Price | 32,206 £0.0000 | ||||
e) | Date of the transaction | 2019-02-15 | |||
f) | Place of the transaction
| n/a | |||
1. | Details of PDMR/person closely associated with them ('PCA') |
| ||||
a) | Name | Mr D Redfern |
| |||
b) | Position/status | Chief Strategy Officer |
| |||
c) | Initial notification/ amendment | Initial Notification |
| |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| ||||
a) | Name | GlaxoSmithKline plc |
| |||
b) | LEI | 5493000HZTVUYLO1D793 |
| |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
| |||
b) | Nature of the transaction | The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 15 February 2019 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. |
| |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
| |
| £15.878 | 9,545 (Deferred) |
| |||
| £15.878 | 5,631 (Matching) |
| |||
|
|
|
| |||
d) | Aggregated information |
|
| |||
Aggregated volume Price | 15,176 £15.878 |
| ||||
e) | Date of the transaction | 2019-02-15 |
| |||
f) | Place of the transaction
| London Stock Exchange (XLON) |
| |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms C Thomas | |||
b) | Position/status | SVP, Human Resources | |||
c) | Initial notification/ amendment | Initial Notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Nature of the transaction | The exercise of nil-cost options over Ordinary Shares granted on 11 February 2016 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £0.0000 | 29,636 (Deferred) |
| ||
| £0.0000 | 17,488 (Matching) |
| ||
|
|
|
| ||
d) | Aggregated information |
| |||
Aggregated volume Price | 47,124 £0.0000 | ||||
e) | Date of the transaction | 2019-02-15 | |||
f) | Place of the transaction
| n/a | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms C Thomas | |||
b) | Position/status | SVP, Human Resources | |||
c) | Initial notification/ amendment | Initial Notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Nature of the transaction | The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 15 February 2019 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £15.8753 | 13,951 (Deferred) |
| ||
| £15.8753 | 8,232 (Matching) |
| ||
|
|
|
| ||
d) | Aggregated information |
| |||
Aggregated volume Price | 22,183 £15.8753 | ||||
e) | Date of the transaction | 2019-02-15 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
Related Shares:
Glaxosmithkline